Week in Review: aTyr Pharma to Raise $86 Million in IPO

aTyr Pharma, a San Diego-Hong Kong innovative biopharma, filed for an $86 million IPO in the US; Shanghai's Ark Biosciences completed a Series A financing to develop drugs for viral diseases; Rock-One of Hong Kong invested $6.2 million in Israel's BioLight Life Sciences and will commercialize BioLight devices for ophthalmology and oncology in China; Sihuan Pharma began a US-based Phase I clinical trial of its novel pan-HER inhibitor aimed at lung and gastric cancers; Canada's Resverlogix was granted two China patents for a cardiovascular disease treatment; Cytori of San Diego and its China licensee, Lorem Vascular, were granted China clearance to market Cytori's device that processes stem cells from adipose tissue; and Tonghua Dongbao Pharma announced plans to spend $59 million to build a new insulin manufacturing plant. More details.... Stock Symbols: (TASE: BOLT; OTC: BLGTY) (HK: 0460) (TSX: RVX) (NSDQ: CYTX) (SHA: 600867) Share this with colleagues: // //